MedTrace Logo

Study of Osteogenesis Imperfecta Tendon

NCT06065111 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2023-10-03

No results posted yet for this study

Summary

Osteogenesis imperfecta (OI) is a rare genetic disease due to a mutation in one of the genes encoding either type I collagen or a protein involved in its synthesis. This leads to bone fragility with fractures and deformities. However, other tissues rich in type I collagen can also be affected, such as teeth or vessel walls.

In the literature, several case reports describe tendon ruptures in OI patients, but no original study has really addressed this issue, which is likely to impact the quality of life through a reduction in mobility and pain.

Recent work carried out by the investigators shows an alteration of the osteotendinous unit in the osteogenesis imperfecta mouse (oim), a validated model of the most severe form of OI. Consequently, the project aims to study the damage of tendon and ligament in patients suffering from osteogenesis imperfecta.

Conditions

Interventions

OTHER

study tendon damage in osteogenesis imperfecta patients

* To identify and characterize alterations of tendons and ligaments in patients with osteogenesis imperfecta (OI) and to improve clinical management of the disease. * To analyze interactions of different parameters, such as laxity or administration of bisphosphonates, on the evolution of the disease.

Sponsors & Collaborators

  • Hopital Lariboisière

    collaborator OTHER

  • University Hospital, Lille

    collaborator OTHER

  • Cliniques universitaires Saint-Luc- Université Catholique de Louvain

    collaborator OTHER

  • Université Catholique de Louvain

    lead OTHER

Principal Investigators

  • Pierre-Louis Docquier, MD · Cliniques Univresitaires Saint-Luc

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-13
Primary Completion
2024-12-31
Completion
2025-06-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06065111 on ClinicalTrials.gov